WO2004046722A3 - Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen - Google Patents

Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen Download PDF

Info

Publication number
WO2004046722A3
WO2004046722A3 PCT/EP2003/012531 EP0312531W WO2004046722A3 WO 2004046722 A3 WO2004046722 A3 WO 2004046722A3 EP 0312531 W EP0312531 W EP 0312531W WO 2004046722 A3 WO2004046722 A3 WO 2004046722A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular diseases
scd40l
plgf
papp
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/012531
Other languages
English (en)
French (fr)
Other versions
WO2004046722A2 (de
Inventor
Andreas M Zeiher
Christopher Heeschen
Stefanie Dimmeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32327495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004046722(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002153525 external-priority patent/DE10253525A1/de
Priority claimed from DE2003116059 external-priority patent/DE10316059A1/de
Priority to DE50309809T priority Critical patent/DE50309809D1/de
Priority to US10/534,985 priority patent/US8409815B2/en
Priority to CA2509063A priority patent/CA2509063C/en
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Priority to JP2004570272A priority patent/JP4741249B2/ja
Priority to EP03779880A priority patent/EP1561116B9/de
Priority to AU2003288027A priority patent/AU2003288027A1/en
Publication of WO2004046722A2 publication Critical patent/WO2004046722A2/de
Publication of WO2004046722A3 publication Critical patent/WO2004046722A3/de
Anticipated expiration legal-status Critical
Priority to US13/613,010 priority patent/US8673581B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft neue Marker der vaskulären Entzündung und Kombinationen davon als Werkzeuge zur Diagnose und deren Prognose in Patienten mit kardiovaskulären Erkrankungen. Die Marker dienen weiterhin als Werkzeuge, die die Auswahl von Wirkstoffen zur Behandlung solcher Erkrankungen erleichtern und schliesslich als Ansatzpunkt für die Behandlung von kardiovaskulären Erkrankungen. Weiterhin betrifft die Erfindung die Erstellung eines individuellen Risikoprofils von negativen Vorgängen, die mit dem Fortschreiten der Arteriosklerose zusammenhängen.
PCT/EP2003/012531 2002-11-16 2003-11-10 Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen Ceased WO2004046722A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003288027A AU2003288027A1 (en) 2002-11-16 2003-11-10 Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
EP03779880A EP1561116B9 (de) 2002-11-16 2003-11-10 Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
JP2004570272A JP4741249B2 (ja) 2002-11-16 2003-11-10 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
US10/534,985 US8409815B2 (en) 2002-11-16 2003-11-10 sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases
CA2509063A CA2509063C (en) 2002-11-16 2003-11-10 Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
DE50309809T DE50309809D1 (de) 2002-11-16 2003-11-10 Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
US13/613,010 US8673581B2 (en) 2002-11-16 2012-09-13 sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10253525.6 2002-11-16
DE2002153525 DE10253525A1 (de) 2002-11-16 2002-11-16 sCD 40L als biochemischer Marker bei kardiovaskulären Erkrankungen
DE10316059.0 2003-04-08
DE2003116059 DE10316059A1 (de) 2003-04-08 2003-04-08 Plazentaler-Wachstumsfaktor (PIGF) als biochemischer Marker bei kardiovaskulären Erkrankungen

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/534,985 A-371-Of-International US8409815B2 (en) 2002-11-16 2003-11-10 sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases
US13/613,010 Continuation US8673581B2 (en) 2002-11-16 2012-09-13 sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases

Publications (2)

Publication Number Publication Date
WO2004046722A2 WO2004046722A2 (de) 2004-06-03
WO2004046722A3 true WO2004046722A3 (de) 2004-08-26

Family

ID=32327495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012531 Ceased WO2004046722A2 (de) 2002-11-16 2003-11-10 Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen

Country Status (9)

Country Link
US (2) US8409815B2 (de)
EP (2) EP1962096B1 (de)
JP (1) JP4741249B2 (de)
AT (1) ATE394679T1 (de)
AU (1) AU2003288027A1 (de)
CA (1) CA2509063C (de)
DE (1) DE50309809D1 (de)
ES (2) ES2305541T3 (de)
WO (1) WO2004046722A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9267954B2 (en) 2007-03-08 2016-02-23 The Governing Council Of The University Of Toronto Use of SLIM-1 in the assessment of heart failure

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962096B1 (de) 2002-11-16 2012-07-18 Siemens Healthcare Diagnostics Products GmbH SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
EP1615035B1 (de) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
EP1615036B1 (de) * 2004-07-07 2007-09-19 F.Hoffmann-La Roche Ag Kombination von Markern für Diabetes Typ 1 und 2
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP1839056B1 (de) * 2004-12-21 2011-08-03 Yale University Präeklampsie-diagnose
CN101185000A (zh) * 2005-03-29 2008-05-21 因弗因斯医药瑞士股份有限公司 监测患者的方法和装置
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
PT2021796E (pt) * 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
ATE476665T1 (de) * 2006-09-20 2010-08-15 Hoffmann La Roche Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion
JP5240945B2 (ja) 2006-11-28 2013-07-17 ピクター リミテッド アッセイ膜およびその使用法
EP2090891A1 (de) * 2008-02-13 2009-08-19 F.Hoffmann-La Roche Ag Mittel und Verfahren zur Bestimmung der atherosklerotischen Last unter Verwendung von Biomarker-PLGF
CA2716522A1 (en) * 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
EP2294426A1 (de) * 2008-05-27 2011-03-16 F. Hoffmann-La Roche AG Verfahren zur risikominderung bei der glykämiekontrolle
JP2011522239A (ja) * 2008-05-29 2011-07-28 エフ．ホフマン−ラ ロシュ アーゲー 心筋トロポニン、ｓＣＤ４０ＬおよびＣ反応性タンパク質の測定に基づく心臓療法に感受性の被験体を特定する手段および方法
WO2010001613A1 (ja) * 2008-07-02 2010-01-07 富士通株式会社 マイクロミラーアレイ、及び、光スイッチ
US20110294683A1 (en) * 2008-10-30 2011-12-01 Centre de Recherche Public de la Sant'e Biomarkers
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2011063470A1 (en) 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
EP2311865A1 (de) * 2010-11-19 2011-04-20 F. Hoffmann-La Roche AG Plazentawachstumsfaktor in Krebsdiagnostik
CN102175873A (zh) * 2011-01-11 2011-09-07 江苏迈迪基因生物科技有限公司 心脑血管疾病蛋白标志物的联合并行检测方法及其诊断试剂盒
EP3441768A3 (de) 2013-08-26 2019-03-20 Roche Diagnostics GmbH Marker zur statinbehandlungsstratifikation bei herzversagen
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN116547537A (zh) 2020-07-29 2023-08-04 皮克托有限公司 SARS-CoV-2抗体免疫测定
WO2024037387A1 (en) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Blood biomarkers and methods for diagnosis of acute kawasaki disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020155A1 (en) * 1996-11-08 1998-05-14 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Diagnostic methods using cd40 ligand assay
WO2001056593A2 (en) * 2000-02-04 2001-08-09 D.Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
WO2002056015A1 (en) * 2001-01-12 2002-07-18 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
WO2003040691A2 (en) * 2001-11-05 2003-05-15 The Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US6333397B1 (en) * 1989-04-25 2001-12-25 Roche Diagnostics Gmbh Monoclonal antibodies to troponin T and their production
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US5821223A (en) 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1998028006A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
US6596501B2 (en) * 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
JP2003509011A (ja) 1999-06-03 2003-03-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 脈管形成タンパク質およびそれらの使用
PT1297016E (pt) 2000-05-12 2006-07-31 Vlaams Interuniv Inst Biotech Utilizacao de inibidores de factor de crescimento placentario para o tratamento da angiogenese patologica, da arteriogenese patologica, da inflamacao, da formacao de tumores e/ou das figas vasculares
WO2002009683A2 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6861504B2 (en) * 2001-05-03 2005-03-01 Cbr, Inc. Compounds and methods for the modulation of CD154
US20040247597A1 (en) 2001-06-20 2004-12-09 Peter Carmeliet Method of treating atherosclerosis and other inflammatory diseases
WO2003040692A2 (en) 2001-11-08 2003-05-15 Vanderbilt University Method for modeling signal transduction in cells
ITRM20020277A1 (it) 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
KR101215701B1 (ko) * 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
EP1962096B1 (de) 2002-11-16 2012-07-18 Siemens Healthcare Diagnostics Products GmbH SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen
EP1530047A1 (de) 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
EP1615036B1 (de) 2004-07-07 2007-09-19 F.Hoffmann-La Roche Ag Kombination von Markern für Diabetes Typ 1 und 2
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
WO2007041614A2 (en) * 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020155A1 (en) * 1996-11-08 1998-05-14 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Diagnostic methods using cd40 ligand assay
WO2001056593A2 (en) * 2000-02-04 2001-08-09 D.Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
WO2002056015A1 (en) * 2001-01-12 2002-07-18 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
WO2003040691A2 (en) * 2001-11-05 2003-05-15 The Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AUKRUST PAL ET AL: "Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes", CIRCULATION, vol. 100, no. 6, 10 August 1999 (1999-08-10), pages 614 - 620, XP002273046, ISSN: 0009-7322 *
BAYES-GENIS ANTONI ET AL: "Pregnancy-associated plasma protein A as a marker of acute coronary syndromes", NEW ENGLAND JOURNAL OF MEDICINE, vol. 345, no. 14, 4 October 2001 (2001-10-04), pages 1022 - 1029, XP002909589, ISSN: 0028-4793 *
BAYES-GENIS ANTONIO ET AL: "Identification of pregnancy-associated plasma protein A (PAPP-A) as a new marker of acute coronary syndromes", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 37, no. 2 Supplement A, February 2001 (2001-02-01), 50th Annual Scientific Session of the American College of Cardiology;Orlando, Florida, USA; March 18-21, 2001, pages 301A, XP008028486, ISSN: 0735-1097 *
DENKTAS A E ET AL: "PREGNANCY ASSOCIATED PLASMA PROTEIN-A LEVELS ARE ELEVATED IN PATIENTS WITH UNSTABLE ANGINA", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 23, no. ABSTR SUPPL, 31 August 2002 (2002-08-31), pages 466, XP008028493, ISSN: 0195-668X *
FUTTERMAN LAURIE G ET AL: "Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A.", AMERICAN JOURNAL OF CRITICAL CARE : AN OFFICIAL PUBLICATION, AMERICAN ASSOCIATION OF CRITICAL-CARE NURSES. MAR 2002, vol. 11, no. 2, March 2002 (2002-03-01), pages 168 - 172, XP008031012, ISSN: 1062-3264 *
GARLICHS C D ET AL: "Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets", HEART (LONDON), vol. 86, no. 6, December 2001 (2001-12-01), pages 649 - 655, XP008028515, ISSN: 1355-6037 *
HAJEK P ET AL: "Pregnancy-associated plasma protein a (PAPP-A) in determination of unstable coronary plaque.", EUROPEAN HEART JOURNAL, vol. 23, no. Abstract Supplement, 2002, & CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY; BERLIN, GERMANY; AUGUST 31-SEPTEMBER 04, 2002, pages 293, XP008028492, ISSN: 0195-668X *
HEESCHEN CHRISTOPHER ET AL: "CD40 ligand serum levels independently predicts outcome and effect of anti-platelet therapy in patients with unstable angina.", CIRCULATION, vol. 106, no. 19 Supplement, 5 November 2002 (2002-11-05), Abstracts from Scientific Sessions;Chicago, IL, USA; November 17-20, 2002, pages II.402, XP008028499, ISSN: 0009-7322 (ISSN print) *
KHOSRAVI JAVAD ET AL: "Pregnancy associated plasma protein-A: Ultrasensitive immunoassay and determination in coronary heart disease.", CLINICAL BIOCHEMISTRY, vol. 35, no. 7, October 2002 (2002-10-01), pages 531 - 538, XP001188913, ISSN: 0009-9120 *
LUTTUN A ET AL: "Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 8, no. 8, August 2002 (2002-08-01), pages 831 - 840, XP002258708, ISSN: 1078-8956 *
MAGLIONE D ET AL: "RECOMBINANT PRODUCTION OF PIGF-1 AND ITS ACTIVITY IN ANIMAL MODELS", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 55, 2000, pages 165 - 167, XP001000056, ISSN: 0014-827X *
PENG DAO-QUAN ET AL: "Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome", CLINICA CHIMICA ACTA, vol. 319, no. 1, 7 May 2002 (2002-05-07), pages 19 - 26, XP002273045, ISSN: 0009-8981 *
SCHONBECK UWE ET AL: "Soluble CD40L and cardiovascular risk in women", CIRCULATION, vol. 104, no. 19, 6 November 2001 (2001-11-06), pages 2266 - 2268, XP002273044, ISSN: 0009-7322 *
VARO NEREA ET AL: "Soluble CD40L: risk prediction after acute coronary syndromes.", CIRCULATION. UNITED STATES 2 SEP 2003, vol. 108, no. 9, 2 September 2003 (2003-09-02), pages 1049 - 1052, XP002273047, ISSN: 1524-4539 *
YAN JINCHUAN ET AL: "Clinical implications of increased expression of CD40L in patients with acute coronary syndromes", CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 115, no. 4, April 2002 (2002-04-01), pages 491 - 493, XP008028508, ISSN: 0366-6999 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9267954B2 (en) 2007-03-08 2016-02-23 The Governing Council Of The University Of Toronto Use of SLIM-1 in the assessment of heart failure

Also Published As

Publication number Publication date
EP1561116A2 (de) 2005-08-10
EP1962096A2 (de) 2008-08-27
ES2305541T3 (es) 2008-11-01
ES2391313T3 (es) 2012-11-23
EP1962096A3 (de) 2008-09-24
EP1561116B1 (de) 2008-05-07
US8673581B2 (en) 2014-03-18
CA2509063C (en) 2010-11-02
CA2509063A1 (en) 2004-06-03
WO2004046722A2 (de) 2004-06-03
JP4741249B2 (ja) 2011-08-03
AU2003288027A1 (en) 2004-06-15
US20130004487A1 (en) 2013-01-03
AU2003288027A8 (en) 2004-06-15
US20070042438A1 (en) 2007-02-22
ATE394679T1 (de) 2008-05-15
EP1962096A9 (de) 2008-11-12
DE50309809D1 (de) 2008-06-19
EP1962096B1 (de) 2012-07-18
US8409815B2 (en) 2013-04-02
EP1561116B9 (de) 2009-04-01
JP2006508367A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
WO2004046722A3 (de) Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2003080801A3 (en) Adipose stromal stem cells for tissue and vascular modification
WO2005039505A3 (en) Compositions and methods for healthy pregnancy
WO2000072015A3 (en) Diagnostics and therapeutics for cardiovascular disorders
WO2006011810A3 (en) Mr imaging method for the discrimination between healthy and tumour tissue
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
AU2003231554A1 (en) Antibody to human insulin-like growth factor
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004047792A3 (de) Liposomale glucocorticoide
WO2006017746A3 (en) Devices and methods of screening for neoplastic and inflammatory disease
WO2003024308A3 (en) Methods of assaying connective tissue growth factor
EP1270044A3 (de) Biomarker für Wundheilung
WO2003066885A3 (en) Method for screening for compounds having hdac inhibitory activity
EP2292257A3 (de) Zusammensetzungen und verfahren zur heilung von hautwunden
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005067956A3 (en) Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
WO2006102979A3 (de) Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
FR2849596B1 (fr) Composition pour le traitement d'une peau a tendance acneique
WO2004110365A3 (en) Liver related disease compositions and methods
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
ATE422500T1 (de) Neue chelidonin-derivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003779880

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004570272

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2509063

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003779880

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007042438

Country of ref document: US

Ref document number: 10534985

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10534985

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003779880

Country of ref document: EP